首页> 美国卫生研究院文献>Disease Markers >Pituitary Tumor-Transforming Gene 1 Is Expressed in Primary Ductal Breast Carcinoma Lymph Node Infiltration and Distant Metastases
【2h】

Pituitary Tumor-Transforming Gene 1 Is Expressed in Primary Ductal Breast Carcinoma Lymph Node Infiltration and Distant Metastases

机译:垂体肿瘤转化基因1在原发性导管乳癌淋巴结浸润和远处转移中表达。

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Despite the advances that have been made in the fields of molecular and cell biology, there is still considerable debate explaining how the breast cancer cells progress through carcinogenesis and acquire their metastatic ability. The lack of preventive methods and effective therapies underlines the pressing need to identify new biomarkers that can aid early diagnosis and may be targets for effective therapeutic strategies. In this study we explore the pituitary tumor-transforming gene 1 (PTTG1) expression in primary ductal breast carcinoma, lymph node infiltration, and distant metastases. Three human cell lines, 184B5 derived from normal mammary epithelium, HCC70 from a primary ductal carcinoma, and MDA-MB-361 from a breast metastasis, were used for quantifying PTTG1 mRNA expression. The PTTG1 immunohistochemical expression was carried out on specimens taken from eight patients with invasive ductal breast cancer who underwent surgical treatment and followup for five years retrospectively selected. The study demonstrated that PTTG1 is expressed gradually in primary ductal breast carcinoma, lymph node infiltration, and distant metastases. Our findings suggest that the immunohistochemical evaluation of PTTG1 expression might be a powerful biomarker of recognition and quantification of the breast cancer cells in routine pathological specimens and a potential target for developing an effective immunotherapeutic strategy for primary and metastatic breast cancer.
机译:尽管在分子和细胞生物学领域已经取得了进步,但是仍然有相当多的争论来解释乳腺癌细胞如何通过致癌作用发展并获得其转移能力。缺乏预防方法和有效疗法的强调强调了寻找新的生物标志物的迫切需要,这些标志物可以帮助早期诊断,并可能成为有效治疗策略的目标。在这项研究中,我们探讨垂体肿瘤转化基因1(PTTG1)在原发性导管癌,淋巴结浸润和远处转移中的表达。三种人类细胞系,分别来自正常乳腺上皮的184B5,来自原发性导管癌的HCC70和来自乳腺转移的MDA-MB-361,用于定量PTTG1 mRNA的表达。 PTTG1免疫组织化学表达是对8例浸润性导管癌患者的标本进行的,这些患者接受了手术治疗并随访了5年。研究表明,PTTG1在原发性导管癌,淋巴结浸润和远处转移中逐渐表达。我们的发现表明,PTTG1表达的免疫组织化学评估可能是识别和定量常规病理标本中乳腺癌细胞的有力生物标志物,并且是开发针对原发性和转移性乳腺癌的有效免疫治疗策略的潜在目标。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号